Compare Acarix AB with Similar Stocks
Stock DNA
Pharmaceuticals & Biotechnology
SEK 337 Million (Micro Cap)
NA (Loss Making)
NA
0.00%
-0.48
-125.98%
8.83
Revenue and Profits:
Net Sales:
2 Million
(Quarterly Results - Dec 2025)
Net Profit:
-12 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-1.25%
0%
-1.25%
6 Months
-9.49%
0%
-9.49%
1 Year
8.22%
0%
8.22%
2 Years
5.13%
0%
5.13%
3 Years
-29.84%
0%
-29.84%
4 Years
-51.56%
0%
-51.56%
5 Years
-68.83%
0%
-68.83%
Acarix AB for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
27.67%
EBIT Growth (5y)
-3.40%
EBIT to Interest (avg)
-63.35
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.75
Sales to Capital Employed (avg)
0.13
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
7.05
EV to EBIT
-4.93
EV to EBITDA
-5.23
EV to Capital Employed
19.66
EV to Sales
54.69
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-399.18%
ROE (Latest)
-128.99%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
Bearish
No Signal
Bollinger Bands
Bearish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Bullish
Dow Theory
No Trend
No Trend
OBV
Mildly Bearish
Mildly Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ
Dec'25
Sep'25
Change(%)
Net Sales
2.10
2.40
-12.50%
Operating Profit (PBDIT) excl Other Income
-11.10
-8.30
-33.73%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-11.70
-9.40
-24.47%
Operating Profit Margin (Excl OI)
-5,583.80%
-3,905.10%
-167.87%
USD in Million.
Net Sales
QoQ Growth in quarter ended Dec 2025 is -12.50% vs 118.18% in Sep 2025
Consolidated Net Profit
QoQ Growth in quarter ended Dec 2025 is -24.47% vs 27.13% in Sep 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
7.40
6.20
19.35%
Operating Profit (PBDIT) excl Other Income
-44.50
-65.00
31.54%
Interest
0.00
0.00
Exceptional Items
0.00
-0.60
100.00%
Consolidate Net Profit
-48.10
-66.20
27.34%
Operating Profit Margin (Excl OI)
-6,522.50%
-10,610.40%
408.79%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 19.35% vs 0.00% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 27.34% vs 14.91% in Dec 2024
About Acarix AB 
Acarix AB
Pharmaceuticals & Biotechnology
Acarix AB is a Sweden-based provider of diagnostic solutions for coronary artery disease (CAD). The Company’s primary product CADScor System features phonocardiography technique and algorithms. The CADScor System is fixed with a specific patch to the chest of the patient, with the recording head placed at the forth left intercostal space, and the sensor resting on the sternum. Instructions for the procedure are given on the display for the operator and audio cues guide a patient during the two-minute heart sound recording. After recording, the CAD-score is calculated, and presented on the display of the CADScor Sensor, enabling a physicians, nurses and laboratory technicians to make a rule-out diagnosis.






